NCT05470270 - Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions

Sickle Cell Disease

Interventions

DRUG

Hydroxycarbamide

Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.

Trial Locations (3)

75015

Necker University Hospital, Paris

75019

Robert Debré Hospital, Paris

94000

InterCommunal Hospital Centre of Creteil, Créteil